Latest Entecavir Stories
MILFORD, Mass., March 12, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of hepatitis B and
DOYLESTOWN, Pa., Nov.
Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).
â€¢ 96-week study in a population of nucleos(t)ide-naïve patients with chronic hepatitis B (CHB) infection â€¢ Data presented at the American Association for the Study of Liver Diseases congress
Virus rebound not linked to antiviral drug resistance; more likely associated with not taking medicine ANN ARBOR, Mich., April 27, 2011 /PRNewswire-USNewswire/ -- A rebound of the Hepatitis B virus is common in patients receiving nucleoside analogs for chronic hepatitis B, according to a study from U-M hepatologists.
PARIS, March 1, 2011 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE:BMY) announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine...
HAIKOU, China, June 17 /PRNewswire-Asia/ -- Kun Run Biotechnology, Inc. (the "Company" or "Kun Run") (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection.